Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
The objective is to show non-inferiority of overall survival between four cycles and six
cycles of first-line cisplatin based chemotherapy to determine the optimal duration of
chemotherapy in patients with advanced urothelial carcinoma.